Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Head-To-Head Studies Require Careful Prioritization, NIH Says

Executive Summary

NIH's role in head-to-head studies of pharmaceuticals must recognize the "limits" on the value of large comparative trials, National Institutes of Health Director Elias Zerhouni told Sen. Hillary Clinton (D-N.Y.) during an Oct. 2 hearing
Advertisement

Related Content

Cost-Effectiveness Makes Medicare Bill; Research Agenda Due In 6 Months
Cost-Effectiveness Makes Medicare Bill; Research Agenda Due In 6 Months
AHRQ Stepping Up Cost-Effectiveness Research; Says Key Is Openness
AHRQ Stepping Up Cost-Effectiveness Research; Says Key Is Openness
Advertisement
UsernamePublicRestriction

Register

PS042588

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel